Should de-escalation of bone-targeting agents be standard of care?

被引：0
|
作者：
Awan, A. [1 ]
Hutton, B. [2 ]
Clemons, M. [3 ,4 ]
机构：
[1] McGill Univ, Div Med Oncol, Dept Oncol, Montreal, PQ, Canada
[2] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
[3] Ottawa Hosp Canc Ctr, Div Med Oncol, Ottawa, ON, Canada
[4] Ottawa Hosp Res Inst, Ottawa, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷 / 05期
关键词：
BREAST-CANCER; PHASE-II; METASTASES; DENOSUMAB; EFFICACY; SAFETY; TRIAL;
D O I：
10.1093/annonc/mdy068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1333 / 1334
页数：3
相关论文
共 27 条
  • [1] Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis
    Liu, C.
    Wang, L.
    Zhuang, J.
    Liu, L.
    Zhou, C.
    Feng, F.
    Sun, C.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1329 - 1330
  • [2] Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis
    Ibrahim, M. F. K.
    Mazzarello, S.
    Shorr, R.
    Vandermeer, L.
    Jacobs, C.
    Hilton, J.
    Hutton, B.
    Clemons, M.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2205 - 2213
  • [3] De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis
    Awan, Arif Ali
    Hutton, Brian
    Hilton, John
    Mazzarello, Sasha
    Van Poznak, Catherine
    Vandermeer, Lisa
    Bota, Brianne
    Stober, Carol
    Sienkiewicz, Marta
    Fergusson, Dean
    Shorr, Risa
    Clemons, Mark
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (03) : 507 - 517
  • [4] De-escalation in DCIS Care
    Nash, Amanda L. L.
    Wang, Sabrina
    McDuff, Susan
    Hwang, E. Shelley
    CURRENT BREAST CANCER REPORTS, 2023, 15 (01) : 58 - 68
  • [5] De-escalation in DCIS Care
    Amanda L. Nash
    Sabrina Wang
    Susan McDuff
    E. Shelley Hwang
    Current Breast Cancer Reports, 2023, 15 : 58 - 68
  • [6] De-escalation of bone-targeted agents for metastatic prostate cancer
    Hong, Brian Younho
    Ibrahim, Mohammed F. K.
    Fernandes, Ricardo
    Mazzarello, Sasha
    Hutton, Brian
    Shorr, Risa
    Clemons, Mark
    CURRENT ONCOLOGY, 2016, 23 (01) : E77 - E78
  • [7] De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times?
    Awan, Arif A.
    Paterson, Alexander
    Clemons, Mark
    JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (08) : 465 - +
  • [8] Treading carefully in de-escalation for bone-targeted agents - is less more, after all?
    Patrikidou, Anna
    Cathomas, Richard
    EUROPEAN JOURNAL OF CANCER, 2021, 142 : 141 - 142
  • [9] Efficacy and safety of de-escalation bone-modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis
    Liu, Cun
    Wang, Lu
    Liu, Lijuan
    Zhuang, Jing
    Tang, Shifeng
    Zhang, Tiansong
    Zhou, Chao
    Feng, Fubin
    Liu, Ruijuan
    Zhang, Jinmei
    Zhang, Tingting
    Gao, Chundi
    Li, Huayao
    Li, Jia
    Sun, Changgang
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3809 - 3823
  • [10] Novel bone-targeting agents in prostate cancer
    Albany, C.
    Hahn, N. M.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2014, 17 (02) : 112 - 118
123